Robotic Mitral Valve Surgery Combined with Left Atrial Reduction and Ablation Procedures

Unal Aydin¹, MD; Onur Sen¹, MD; Ersin Kadirogullari¹, MD; Zeynep Kahraman², MD; Burak Onan¹, MD

Abstract

Introduction: This study aimed to evaluate the feasibility and efficacy of robotically assisted, minimally invasive mitral valve surgery combined with left atrial reduction for mitral valve surgery and elimination of atrial fibrillation (AF).

Methods: Eleven patients with severe mitral regurgitation, AF, and left atrial enlargement who underwent robotic, minimally invasive surgery between May 2013 and March 2018 were evaluated retrospectively. The da Vinci robotic system was used in all procedures. The patients’ demographic data, electrocardiography (ECG) findings, and pre- and postoperative transthoracic echocardiography findings were analyzed. During follow-up ECG was performed at postoperative 3, 6, and 12 months additionally at the 3rd month trans thoracic echocardiography was performed and functional capacity was also evaluated for all patients.

Results: All patients underwent robotic-assisted mitral valve surgery with radiofrequency ablation and left atrial reduction. Mean age was 45.76±16.61 years; 7 patients were male and 4 were female. Preoperatively, mean left atrial volume index (LAVI) was 69.55±4.87 mL/m², ejection fraction (EF) was 54.62±8.27%, and pulmonary artery pressure (PAP) was 45.75±9.42 mmHg. Postoperatively, in hospital evaluation LAVI decreased to 48.01±4.91 mL/m² (P=0.008), EF to 50.63±10.13% (P>0.05), and PAP to 39.02±3.11 mmHg (P=0.012). AF was eliminated in 8 (72%) of the 11 patients at the 1st postoperative month. There were significant improvements in functional capacity and no mortality during follow-up.

Conclusion: Left atrial reduction and radiofrequency ablation concomitant with robotically assisted minimally invasive mitral valve surgery can be performed safely and effectively to eliminate AF and prevent recurrence.

Keywords: Robotic Cardiac Surgery. Left Atrial Enlargement. Atrial Fibrillation.

INTRODUCTION

Robotic-assisted surgical platforms are the next step in the evolution of minimally invasive endoscopic procedures, and robotic surgery has become increasingly popular over the last two decades[1-5]. The main advantages of these systems are less pain, shorter hospital stay, faster recovery, and improved cosmesis. The da Vinci system (Intuitive Surgical, CA, USA) is the most widely used robotic system. In addition to providing three-dimensional imaging and motion-scaled, tremor-free movements, it improves surgeon dexterity and enables ambidextrous instrument usage.

Atrial fibrillation (AF) and left atrial enlargement (LAE) are coexisting pathologies of mitral valve disorders[6]. Although successful mitral valve reconstruction reduces left atrial pressure, fibrosis and LAE are irreversible[7]. Surgical reconstruction of the left atrium aims to restore synchronous left heart functions and reduce the likelihood of AF recurrence[8]. Although robotic mitral valve surgery is well documented,
there are no reports in the literature concerning the combination of mitral valve surgery, radiofrequency (RF) ablation, and left atrial reduction. Therefore, the aim of this study was to provide further validation of the efficacy and feasibility of robotic-assisted surgical techniques for this combined procedure.

**METHODS**

Between May 2014 and March 2018, a total of 440 patients underwent cardiac operations (due to coronary artery disease, valve disease, atrial septal defect, and cardiac tumors) using the da Vinci robotic system. Mitral valve surgery was performed on 122 (28%) of those patients, 11 (9%) of whom were diagnosed with severe mitral regurgitation, AF, and LAE. Data pertaining to these 11 patients were analysed retrospectively (Table 1). Informed consent was obtained from the patients and the study was approved by a local ethics committee. All patients underwent transthoracic and transesophageal echocardiography, coronary angiography, and Doppler ultrasound of the femoral arteries during preoperative evaluation period. Patients with coronary artery disease, severe peripheral artery disease, sternal or right thoracic reoperations, and emergency surgeries were excluded. However, patients with tricuspid valve disease were included in the study. Extensive pleural adhesions, poor pulmonary function, poor ventricular function, aortic regurgitation, and pectus excavatum are relative contraindications for robotic mitral valve surgery. The patients’ mean Logistic EuroSCORE was 3.88±1.05. Criteria for undergoing mitral valve surgery were presence of symptomatic chronic severe mitral regurgitation (vena contracta >0.5 cm, regurgitant volume >60 ml per beat) with an ejection fraction (EF) >30% and left ventricular end systolic diameter (LVESD) <55 mm, or asymptomatic severe mitral regurgitation with EF <60% and LVESD >40 mm (Table 2). Surgical RF ablation was performed in patients with persistent AF for more than 7 days despite antiarrhythmic drug therapy. Patients with left atrial diameter >5.5 cm also underwent left atrial reduction. The left atrial anteroposterior, mediolateral, and superoinferior diameters were measured by the same cardiologist. These values were used to determine left atrial volume and calculate left atrial volume index (LAVI).

**Robotic System Setup**

A left radial artery catheter was placed, and general anesthesia was induced, followed by placement of a single-lumen endotracheal tube and transesophageal echocardiography (TEE) probe. After surgical cannulation of the femoral artery and vein, the jugular and femoral vein catheters were connected to each other, then both arterial and venous cannulas were connected to the cardiopulmonary circuit. The da Vinci robotic system was docked, and the robotic arms were deployed to the designated intrathoracic space (Figure 1). Cardiopulmonary bypass (CPB) was initiated and pericardiectomy was performed, being careful to avoid the phrenic nerve. The pericardium was suspended using retraction sutures. The anterolateral surface of the ascending aorta was sutured with 5-0 PTFE suture for cardioplegia cannula fixation. This cannula can also be used as an aortic root vent. The

---

**Table 1. Baseline and datas.**

| Age (mean±standard deviation) | 45.7±16.6 |
| Sex (Male/female) (n) | 07-4 |
| Diabetes Mellitus (n) | 3 |
| Hypertension (n) | 4 |
| COPD (n) | 0 |
| Renal failure (n) | 0 |
| Previous Stroke (n) | 0 |
| Atrial fibrillation | 11 |
| Left atrial thrombus | 1 |
| COPD=Chronic obstructive pulmonary disease |

**Table 2. Echocardiography datas.**

| Mitral valvular pathology |  |
| Myxomatous degeneration (n) | 6 |
| Ischemic regurgitation (n) | 0 |
| Functional reg (n) | 0 |
| Rheumatic reg. (n) | 5 |
| Tricuspid reg. (n) | 3 |
| Ejection fraction | 54.62±8.27 |
| LVEDD (cm) | 5.76±0.35 |
| LVESD (cm) | 4.08±0.40 |
| meanPAP (mmHg) | 45.75±9.42 |
| LAVI (mL/m²) | 69.55±4.87 |

LAVI=left atrial volume index; LVEDD=left ventricle end diastolic diameter; LVESD=left ventricle end systolic diameter; PAP=pulmonary artery pressure

---

**Fig. 1 - Robotic left atrial reduction procedure.**
Follow Up

Every patient was followed up for 3 months exactly because patients were started on class I or III antiarrhythmic drugs and warfarin before hospital discharge. The rhythm was monitored continuously until the discharge, for all patients. If they were in sinus rhythm at the 3rd month, the antiarrhythmic drugs were discontinued. Furthermore, if sinus rhythm was obtained and mitral repair was durable concomitantly by means of echocardiography, anticoagulation was stopped. Follow up conducted by obtaining electrocardiograms studies for all patients at 3, 6 and 12 months and trans thoracic echocardiography studies and functional capacity analysis was performed for all patients at the 3rd month (Tables 3 and 4).

**Statistical Analyses**

All analyses were conducted using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as mean ± SD and categorical variables as percentages. Preoperative and postoperative continuous and categorical data were compared with Wilcoxon signed-rank and McNemar tests, respectively. A two-sided $P$ value <0.05 was considered statistically significant.

**RESULTS**

Mitral valve reconstruction, radiofrequency ablation, and left atrial reduction procedures were performed concomitantly. Left atrial appendage closure was performed in all cases as part of the left atrial reduction procedure. There was no operative or hospital mortality. Bleeding, re-operation, stroke, renal failure or infection did not occur during in hospital and follow up period. Mean CPB time was 147.88±19.12 minutes and mean XC time was 105.75±20.03 minutes. Sinus rhythm was achieved in 8 of 11 patients (72.7%) at postoperative week 1 (Table 5). The mean follow-up time was 16.30±5.42 months, during which there was no mortality. However, the proportion of patients maintaining sinus rhythm decreased during follow-up. One patient experienced AF recurrence despite antiarrhythmic medication. Postoperative mean LAVI was significantly lower compared to the preoperative value (48.01±4.91 mL/m$^2$ vs. 69.55±4.87 mL/m$^2$, $P$=0.008) (Table 3).

**Table 3.** Statistical analyses of echocardiographic datas.

|                      | Preoperative | Postoperative | $P$  |
|----------------------|--------------|---------------|------|
| Ejection fraction    | 55.22±7.93   | 50.63±10.13   | 0.059|
| meanPAP (mmHg)       | 47.44±9.98   | 39.02±3.11    | 0.012|
| LAVI (mL/m$^2$)      | 69.55±4.87   | 48.01±4.91    | 0.008|

**Table 4.** Statistical analyses of functional classification.

| NYHA Class | Preoperative | Postoperative | $P$  |
|------------|--------------|---------------|------|
| Class I    | 0            | 3             |      |
| Class II   | 1            | 7             |      |
| Class III  | 7            | 1             | <0.001|
| Class IV   | 3            | 0             |      |

NYHA=New York Heart Association
TABLE 5: Operative and postoperative data.

| Procedure                        | Count |
|----------------------------------|-------|
| Mitral valve repair               | 3     |
| Mitral valve replacement          | 8     |
| Maze procedure                    | 11    |
| Appendage closure                 | 11    |
| Left atrial reduction             | 11    |
| Tricuspid valve repair            | 2     |
| CPB time (min) (mean±standard deviation) | 147.88±19.12 |
| XC time (min) (mean±standard deviation) | 105.75±20.03 |
| Sinus rhythm at hospital discharge (n) | 8     |
| ICU stay (day) (mean±standard deviation) | 1.50±0.53 |
| Hospital stay (day) (mean±standard deviation) | 5.22±1.64 |

AF=atrial fibrillation; CPB=cardiopulmonary bypass; ICU=intensive care unit; XC=cross clamp

Pre- and postoperative mean New York Heart Association (NYHA) classification indicated significant functional improvement postoperatively (3.1±0.6 vs. 1.8±0.6; P<0.001) (Table 4).

DISCUSSION

This study involves the analyses of mitral valve procedures combined with RF ablation and LA reduction procedures via robotic surgery. Mitral valve surgery via robotic-assisted systems enables the surgeon to explore the mitral valve and components in detail without an open procedure. Robotic systems provide three-dimensional visualization and utilize long-shafted endoscopic instruments with seven degrees of freedom. These features enable minimally invasive mitral valve procedures to be performed as successfully as with conventional sternotomy but with reduced trauma, less need for blood and blood products, and shorter intensive care unit and hospital stays. As surgeons use robotic surgical platforms for increasingly complex procedures, it is important to collate clinical data to validate the use of these methods for various surgery types and patient groups. Nifong et al. reported successful surgical management of mitral valve repairs with concomitant bariatric cryoablation via robotic, minimally invasive surgery. In the present study, we report the successful surgical management of mitral valve pathologies with concomitant RF ablation and left atrial reduction through robotic, minimally invasive technique. One concern with increasing the complexity of robotic surgeries may be prolonging CPB and XC times and surgery duration. Robotic surgery is associated with longer XC and CPB times compared to conventional approaches. However, it has been reported that the mortality and morbidity rates are similar to the conventional procedures. In a 2013 systematic review of robotic mitral surgery by Seco et al., reported CPB times ranged from 106±22 to 188.5±53.8 minutes and mean XC times ranged from 79±16 to 140±40 minutes. In the single study that reported CPB and XC times separately for robotic mitral valve surgery with and without cryoablation, CPB times were 188.5±53.8 and 153.2±37.7 minutes and XC times were 130.6±28.4 and 116.6±31.6 minutes respectively with and without cryoablation. The robotic mitral valve surgery we performed consisted of mitral valve repair or replacement, left atrial appendage closure, RF ablation, and left atrial reduction. Nevertheless, our CPB and XC times were 147.88±19.12 and 105.75±20.03 minutes, respectively. These times are well within the ranges reported in the literature for robotic mitral valve surgery and even below those reported for procedures including ablation. This clearly demonstrates that prolonged CPB and XC times is not an issue with concomitant ablation and left atrial reduction procedures in robotic mitral valve surgery. In experienced centers with refined techniques and skilled robotic teams, operative times should be comparable to those achieved with conventional methods. The determination of the interrelationship of pressure, volume, and wall stress of the cardiac chambers is an important prerequisite for a fundamental understanding of cardiac mechanics. A mathematical model of these mechanics is based on the Law of Laplace (P=2HT/r)[14]. In this formula, P is pressure, H is wall stress, T is wall thickness, and r is the radius of the chamber. This equation shows that for a given pressure, an increase in radius requires increased wall thickness to maintain a constant wall stress. Consequently, increased left atrial diameter would cause increased wall thickness. The primary mechanism through which wall thickness is increased is fibrous tissue accumulation, and left atrial fibrosis plays a major role in the development of atrial fibrillation. Based on these data, the surgical strategy used in our practice for patients with mitral valve dysfunction, AF, and LAE is to restore normal mitral function via replacement or repair and to perform RF ablation and LA reduction to restore and maintain normal mechanical functions and rhythm. Consequently, we preferred only left atrial ablation procedure because no significant difference was mentioned between bariatric and left atrial ablation results in previous studies. Duration of mitral valve disease is the main factor for LAE and progression of AF, which may be complicated with cerebral and peripheral thromboembolic events. There is no consensus on performing left atrial reduction; however, an association between left atrial size and failure of the maze procedure has been reported previously. In another study, AF was eliminated after maze procedure in 100% of patients with left atrial size <4.5 cm and 0% of patients with left atrial size >8.5 cm. In the present study, mean LAVI was 69.55±4.87 mL/m² and sinus rhythm was achieved in 8 patients (72.7%). We believe that reducing left atrial size is an important factor in the elimination of AF and can facilitate better ventricle function. Our results confirm that significant reductions in left atrial volume can be achieved through a robotic surgical platform.

CONCLUSION

Our study demonstrates that performing left atrial reduction is feasible through robotically assisted, minimally invasive mitral valve surgery with RF ablation, and yields satisfactory outcomes in the management of mitral valve pathology with concomitant AF and LAE.

Braz J Cardiovasc Surg 2019;34(3):285-9 Aydin U, et al. - Left Atrial Reduction and Robotic Valve Surgery
This study is limited by the retrospective, single-center nature of the data and the small number of patients. Another limitation was that the study did not directly compare conventional and robotic mitral valve surgeries combined with left atrial reduction and RF. Nevertheless, our initial results are a novel contribution to the literature in terms of validating robotic-assisted surgical techniques.

No financial support.
No conflict of interest.

Authors' roles & responsibilities

**UA** Conception and study design; analysis and/or data interpretation; statistical analysis; final approval of the version to be published

**OS** Conception and study design; analysis and/or data interpretation; statistical analysis; final approval of the version to be published

**EK** Conception and study design; analysis and/or data interpretation; statistical analysis; final approval of the version to be published

**ZK** Conception and study design; analysis and/or data interpretation; statistical analysis; final approval of the version to be published

**BO** Execution of operations and/or trials; manuscript writing or critical review of its content; final approval of the version to be published

REFERENCES

1. Carpentier A, Loulmet D, Aupeville B, et al. [Computer assisted open heart surgery: First case operated on with success]. C R Acad Sci III [Internet]. 1998 [cited 2019 Apr 27];321(5):437–42. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9766192. French

2. Bush B, Nifong LW, Alwair H, Chitwood WR Jr. Robotic mitral valve surgery-current status and future directions. Ann Cardiothorac Surg. 2013;2(6):814-7. doi:10.3978/j.issn.2225-319X.2013.10.04

3. Onan B, Aydin U, Kahraman Z, et al. Robot-assisted mitral valve repair with posterior leaflet extension for rheumatic disease. Innovations. 2017;12(1):60-63. doi:10.1016/j.est.2016.10.017

4. Onan B, Bakir I. Robotic mitral valve replacement in pectus excavatum. J Card Surg. 2016;31(5):306-8. doi:10.1111/jocs.12740

5. Bakir I, Onan B, Kadiroglu I. Robotic assisted repair of partial atrioventricular canal defect. Artif Organs. 2016;40(9):917-8. doi:10.1111/aor.12800

6. Sanfilippo AJ, Abascal VM, Sheehan M, et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation. 1990;82(3):792–7. doi:10.1161/01.CIR.82.3.792

7. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124(20):2264-74. doi:10.1161/CIRCULATIONAHA.111.019893

8. Kamata N, Kawazoe K, Izumoto H, et al. Predictors of sinus rhythm restoration after Cox maze procedure concomitant with other cardiac operations. Ann Thorac Surg. 1997;64(2):394–8. doi:10.1016/S0003-4975(97)00139-2.

9. Woo YJ, Nacke EA. Robotic minimally invasive mitral valve reconstruction yields less blood product transfusion and shorter length of stay. Surgery. 2006;140(2):263-7. doi:10.1016/j.surg.2006.05.003.

10. Nifong LW, Rodriguez E, Chitwood WR Jr. 540 consecutive robotic mitral valve repairs including concomitant atrial fibrillation cryoablation. Ann Thorac Surg. 2012;94(1):38-42; discussion 43. doi:10.1016/j.athoracsur.2011.11.036

11. Cao C, Wolfenden H, Liou K, Pathan F, Gupta S, Nienaber TA, et al. A meta-analysis of robotic vs. conventional mitral valve surgery. Ann Cardiothorac Surg. 2015;4(4):305-14. doi:10.3978/j.issn.2225-319X.2014.10.05

12. Bonaros N, Schachner T, Oehlinger A, et al. Roboticically assisted totally endoscopic atrial septal defect repair: insights from operative times, learning curves, and clinical outcome. Ann Thorac Surg. 2006;82(2):687-93. doi:10.1016/j.jathorac.2006.03.024.

13. Seco M, Cao C, Modí P, Bannón PG, Wilson MK, Vallely MP, et al. Systematic review of robotic minimally invasive mitral valve surgery. Ann Cardiothorac Surg. 2013;2(6):704-16. doi:10.3978/j.issn.2225-319X.2013.10.18

14. Moriarty TF. The law of Laplace. Its limitations as a relation for diastolic pressure, volume, or wall stress of the left ventricle. Circ Res. 1980;46(3):321-31. doi:10.1161/01.RES.46.3.321.

15. Hanif W, Alex L, Su Y, et al. Left atrial remodeling, hypertrophy, and fibrosis in mouse models of heart failure. Cardiovasc Pathol. 2017;30:27-37. doi:10.1016/j.carpath.2017.06.003.

16. Spragg D. Left Atrial Fibrosis: Role in atrial fibrillation pathophysiology and treatment outcomes. J Atr Fibrillation. 2013;5(6):810. doi:10.4022/jafib.810.

17. Churyla A, Iddriss A, Andrei AC, et al. Biatrial or left atrial lesion set for ablation during mitral surgery: risks and benefits. Ann Thorac Surg. 2017;103(6):1858-65. doi:10.1016/j.athoracsur.2016.10.017.

18. Li H, Lin X, Ma X, et al. Biattrial versus isolated left atrial ablation in atrial fibrillation: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:3651212. doi:10.1155/2018/3651212.

19. Kawaguchi AT, Kosakai Y, Isobe F, et al. Surgical stratification of patients with atrial fibrillation secondary to organic cardiac lesions. Eur J Cardiothorac Surg. 1996;10(1):983–9. discussion 989–990. doi:10.1016/S1010-7940(96)80401-5.

20. Kosakai Y. Treatment of atrial fibrillation using the Maze procedure: the Japanese experience. Semin Thorac Cardiovasc Surg. 2000;12(1):44-52. doi:10.1016/S1043-0679(00)70016-5.

This is an open-access article distributed under the terms of the Creative Commons Attribution License.